Daily Diary Scores Measure Success
To evaluate efficacy and tolerability, the
researchers will look primarily at daily
Motherisk-PUQE (pregnancy-unique
quantification of emesis and nausea)
scores. Other measures of effectiveness
will include maternal and fetal outcomes
as well as patients’:
- oral nutrition, or nutrients taken by
mouth versus intravenously
- quality of life
- overall level of satisfaction or
dissatisfaction with the medication
- blood laboratory values
- need for IV hydration or hospital
admission
Prior Results Show Dramatic
Improvements
Guttuso led a pilot study involving seven
hyperemesis gravidarum patients,
published in Early Human Development in
January 2010. After two weeks of
gabapentin therapy, patients’ nausea
decreased by an average of 80 percent
and vomiting decreased by 94 percent.
The research team also included Luther K.
Robinson, MD, professor of pediatrics.
Guttuso’s prior research also has linked
gabapentin with marked reductions in
refractory nausea and vomiting in other
patient populations.
Research Gives Women ‘Renewed
Sense of Hope’
The importance of Guttuso’s research to
women facing hyperemesis gravidarum
is reflected in a Facebook group that
provides information about the use of
gabapentin during pregnancy.
According to one of the group’s
administrators, about 100 people have
joined so far. “These women who
thought they would never be able to
have another child are being given a
renewed sense of hope,” she wrote in a
message to Guttuso.
- See more at:
http://medicine.buffalo.edu/news_and_
events/news.host.html/content/shared/
smbs/news/2014/05/pregnancynausea-drug3644.detail.html#sthash.vGYZ6gDY.dpuf
Click here to join
the Gabapentin
Facebook
Support Group
14